Clene大股东Chidozie Ugwumba出售了11亿美元股票,因为公司损失了钱,毒品试验仍在继续。 Major Clene shareholder Chidozie Ugwumba sold $1.1M in stock as company lost money and drug trials continue.

2025年12月4日至18日,CLNN公司的主要股东Chidozie Ugwumba出售了181 009股股票,价格从570美元到681美元,价值约110万美元。 Major shareholder Chidozie Ugwumba of Clene Inc. (CLNN) sold 181,009 shares between December 4 and 18, 2025, at prices from $5.70 to $6.81, generating about $1.1 million. 销售减少了他的股份,给他留下大约447 891股股票。 The sales reduced his stake, leaving him with approximately 447,891 shares. 该公司报告,每股每季度损失0.85美元,低于预期,收入为20 000美元。 The company reported a quarterly loss of $0.85 per share, below expectations, with $20,000 in revenue. Clene的股票以6.04美元关闭,市场上限为6 239万美元。 Clene’s stock closed at $6.04, with a market cap of $62.39 million. 分析师有一个协商一致的“机动购买”评级和32.60美元目标。 Analysts have a consensus "Moderate Buy" rating and a $32.60 target. 该公司的主要药物CNM-Au8正在第二阶段试验ALS、多发性硬化症和视神经病。 The company’s lead drug, CNM-Au8, is in Phase 2 trials for ALS, multiple sclerosis, and optic neuropathy.